MX2013002150A - Proceso para la preparacion de intermediarios para la elaboracion de inhibidores de nep. - Google Patents

Proceso para la preparacion de intermediarios para la elaboracion de inhibidores de nep.

Info

Publication number
MX2013002150A
MX2013002150A MX2013002150A MX2013002150A MX2013002150A MX 2013002150 A MX2013002150 A MX 2013002150A MX 2013002150 A MX2013002150 A MX 2013002150A MX 2013002150 A MX2013002150 A MX 2013002150A MX 2013002150 A MX2013002150 A MX 2013002150A
Authority
MX
Mexico
Prior art keywords
nep inhibitors
manufacture
intermediates
preparation
amino
Prior art date
Application number
MX2013002150A
Other languages
English (en)
Inventor
David Hook
Jianguang Zhou
Yunzhong Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013002150A publication Critical patent/MX2013002150A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/12—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing organo-metallic compounds or metal hydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a un nuevo proceso para producir intermediarios útiles para la elaboración de inhibidores de NEP o pro-fármacos de los mismos, en particular inhibidores de NEP que comprenden una estructura base de ácido o éster de ácido ?-amino-d-bifenil-a-metil-alcanoico, tal como el etil-éster del ácido N-(3-carboxil-1-oxo-propil)-(4S)-(p-fenil-fenil-metil)-4-ami no-(2R)-metil-butanoico o una sal del mismo.
MX2013002150A 2010-08-23 2011-08-22 Proceso para la preparacion de intermediarios para la elaboracion de inhibidores de nep. MX2013002150A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010076245 2010-08-23
PCT/EP2011/064410 WO2012025501A1 (en) 2010-08-23 2011-08-22 Process for the preparation of intermediates for the manufacture of nep inhibitors

Publications (1)

Publication Number Publication Date
MX2013002150A true MX2013002150A (es) 2013-04-03

Family

ID=44658722

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002150A MX2013002150A (es) 2010-08-23 2011-08-22 Proceso para la preparacion de intermediarios para la elaboracion de inhibidores de nep.

Country Status (14)

Country Link
US (1) US8835668B2 (es)
EP (1) EP2609075B1 (es)
JP (1) JP5705984B2 (es)
KR (1) KR101476937B1 (es)
AU (1) AU2011295170B2 (es)
BR (1) BR112013004164A2 (es)
CA (1) CA2806780A1 (es)
ES (1) ES2576179T3 (es)
MX (1) MX2013002150A (es)
PL (1) PL2609075T3 (es)
PT (1) PT2609075E (es)
RU (1) RU2588572C2 (es)
SI (1) SI2609075T1 (es)
WO (1) WO2012025501A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091364A1 (es) 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
LT3218351T (lt) 2014-11-14 2019-09-25 Zentiva K.S. Ahu-377 farmaciniu požiūriu priimtinų formų gavimo, atskyrimo ir gryninimo būdas
TW201632493A (zh) 2015-02-13 2016-09-16 諾華公司 新穎方法
WO2016135751A1 (en) 2015-02-25 2016-09-01 Mylan Laboratories Limited Novel process for the preparation of sacubitril and its intermediates
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
CA3006254A1 (en) 2015-12-10 2017-06-15 Novartis Ag New process and intermediates
MX2018007129A (es) 2015-12-11 2018-11-09 Zentiva Ks Formas solidas de ester etilico del acido (2r,4s)-5-(bifenil-4-il) -4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un metodo de preparacion.
CN109415308B (zh) 2016-07-05 2022-09-06 诺华股份有限公司 用于早期沙卡布曲中间体的新方法
US10851059B2 (en) 2016-08-17 2020-12-01 Novartis Ag Processes and intermediates for NEP inhibitor synthesis
JP7138106B2 (ja) 2016-12-23 2022-09-15 ノバルティス アーゲー 初期サクビトリル中間体のための新規な方法
CN106946742A (zh) * 2017-03-28 2017-07-14 常州沃腾化工科技有限公司 一种三苯基氧磷含量低的沙库必曲中间体的制备方法
CN109503404A (zh) * 2018-12-28 2019-03-22 凯瑞斯德生化(苏州)有限公司 一种lcz-696关键中间体的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5015793B2 (es) 1972-06-07 1975-06-07
JPS53103412A (en) * 1977-02-18 1978-09-08 Kuraray Co Ltd Preparation of farnesyl acetic acid or its ester
US4219683A (en) * 1978-09-25 1980-08-26 Phillips Petroleum Company Isomerization of unsaturated alcohols
FR2597100A1 (fr) 1986-01-21 1987-10-16 Nippon Shinyaku Co Ltd Derives du pyroglutamide
DE3713127A1 (de) * 1987-04-16 1988-11-03 Consortium Elektrochem Ind Verfahren zur herstellung von tiglinaldehyd
JPH07103101B2 (ja) 1989-07-24 1995-11-08 キッセイ薬品工業株式会社 ピログルタミン酸誘導体
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
US5273990A (en) 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
US5250522A (en) 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
EP0550313A1 (fr) 1991-12-30 1993-07-07 Synthelabo Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
FR2688503B1 (fr) 1992-03-16 1994-05-06 Synthelabo Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle].
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
US5550119A (en) 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
CA2246725A1 (en) 1996-02-19 1997-08-21 Japan Tobacco Inc. Therapeutic agent for diabetes
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE69817974T2 (de) 1997-11-14 2004-07-22 Schering Ag Ein Verfahren zur Herstellung von Pyrrolidinon-Derivaten
CA2344412A1 (en) 1998-09-21 2000-03-30 Takeda Chemical Industries, Ltd. Thiol compound, their production and use
WO2001068591A1 (en) * 2000-03-16 2001-09-20 F. Hoffmann-La Roche Ag Carboxylic acid derivatives as ip antagonists
BRPI0306907B8 (pt) 2002-01-17 2021-05-25 Novartis Ag composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais
ATE473216T1 (de) 2002-03-29 2010-07-15 Senju Pharma Co Hydroxymorpholinonderivat und dessen medizinische verwendung
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
WO2005108409A2 (en) 2004-05-07 2005-11-17 Umicore Ag & Co. Kg Ferrocenyl ligands for homogeneous, enantioselective hydrogenation catalysts
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
EP1903027A1 (en) * 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
MY153432A (en) 2007-01-12 2015-02-13 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
ES2463693T3 (es) 2007-05-10 2014-05-29 R & D Biopharmaceuticals Gmbh Derivados de tubulisina
PE20091364A1 (es) * 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
RU2564024C2 (ru) 2010-01-22 2015-09-27 Новартис Аг Промежуточные продукты для получения ингибиторов нейтральной эндопептидазы и способ их получения
WO2012025502A1 (en) 2010-08-23 2012-03-01 Novartis Ag New process for the preparation of intermediates useful for the manufacture nep inhibitors

Also Published As

Publication number Publication date
ES2576179T3 (es) 2016-07-06
AU2011295170B2 (en) 2014-12-18
US20130158285A1 (en) 2013-06-20
JP5705984B2 (ja) 2015-04-22
RU2588572C2 (ru) 2016-07-10
EP2609075A1 (en) 2013-07-03
AU2011295170A1 (en) 2013-03-21
EP2609075B1 (en) 2016-03-16
JP2013539462A (ja) 2013-10-24
KR20130061735A (ko) 2013-06-11
WO2012025501A1 (en) 2012-03-01
PT2609075E (pt) 2016-06-03
SI2609075T1 (sl) 2016-06-30
US8835668B2 (en) 2014-09-16
CA2806780A1 (en) 2012-03-01
BR112013004164A2 (pt) 2016-05-10
PL2609075T3 (pl) 2016-09-30
RU2013112946A (ru) 2014-09-27
KR101476937B1 (ko) 2014-12-24

Similar Documents

Publication Publication Date Title
MX2013002149A (es) Nuevo proceso para la preparacion de intermediarios utiles para la elaboracion de inhibidores de nep.
MX2013002150A (es) Proceso para la preparacion de intermediarios para la elaboracion de inhibidores de nep.
MX2012008483A (es) Intermediarios de inhibidores de la endopeptidasa neutra y metodo de preparacion de los mismos.
IN2015DN00909A (es)
CY1125155T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
NZ711679A (en) Antimicrobial compositions and related methods of use
MX350211B (es) Proceso para la preparacion del etil-ester del acido n- (4-ciclohexil-3-trifluoro-metil-benciloxi) -acetimidico.
LT2678322T (lt) Furandikarboninės rūgšties pentilo esteris kaip plastifikatorius
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
TW200942513A (en) Process for the preparation of fatty acid alkyl esters
PL2537840T3 (pl) Sposób wytwarzania walerolaktonu z kwasu lewulinowego
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
EP2690086A4 (en) NOVEL CARBOXYLIC ACID ESTER COMPOUND, PROCESS FOR PRODUCING THE SAME, AND SCENTED COMPOSITION
SG195111A1 (en) Process for preparing methacrylic acid
CY1124919T1 (el) Κρυσταλλικη μορφη τριυδριτη toy (3s,3s') 4,4'-δισουλφανοδιυλοδις(3-αμινοβουτανο 1-σουλφονικου οξεος)
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
MX2012002818A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
BR112013009163A2 (pt) processo para preparação de lubiprostona
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
EA201291235A1 (ru) Новые способы
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
IN2014DN03245A (es)
MX369283B (es) Preparacion de 2-amino-5-ciano-n, 3-dimetilbenzamida.
EP2639218A4 (en) NEW CARBOXYLIC ACID ESTER COMPOUND, ITS PREPARATION AND PARFUM COMPOSITION THEREWITH
WO2011141923A3 (en) Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin

Legal Events

Date Code Title Description
FG Grant or registration